GOOD STATISTICAL PRACTICE is continually developing. Although the overall objectives remain the same, the methods by which those objectives are achieved are constantly changing in line with technical developments, changing business or regulatory needs, and technological advances. It follows, therefore, that statistical standard operating procedures (SOPs) must be "live" documents if they are to actively encourage good statistical practice. Consensus on the following issues is key to achieving a common approach to statistical SOPs. ments, this emphasis is changing and many organizations now see a clear business need for SOPs. They should be an aid to process improvement.
Should an SOP be a statement of principle or a detailed set of instructions? -
A detailed set of instructions is helpful in the training of new staff and would probably help the auditor. It is, however, inflexible, difficult to maintain, and inhibits professional freedom.
It is suggested that SOPs should be statements of principle with appropriate options and topics for consideration indicated. It may be appropriate to support these with more detailed guidelines on working practices in some instances such as to assist with staff training.
a ) It is reasonable to suggest that:
1.
What is the purpose of SOPs? -Is it compliance with GCP and other regulatory guidelines or business driven with the emphasis on regulating internal 3. Interfaces and Harmonization quality by setting operational standards (eg, in software development) since rework is costly?
It is both. Although the driving factor in developing SOPs initially has ofThe statistical contribution is part of a multidisciplinary process and consistency of operation and expectation is desirable, and A statistician should review any presentation or interpretations of the data analyzed for statistical validity. If the above are to be achieved the mechanism by which statistical SOPs interface with SOPs from scientific, medical, data management, marketing, and registration groups within the same organization needs careful consideration. It is suggested that collaboration is essential to the quality of the overall process. b) Should SOPs be harmonized at the detailed level or at the level of "statements of principle": In international pharmaceutical companies? Between a sponsor company and a contract research organization? It is suggested that the pragmatic solution is to work to common overall quality standards and principles but that achieving common working practices may be counter-productive. Changing working practices purely to achieve harmonization of SOPs may produce a reduction in quality rather than an improvement, as it may involve considerable culture changes in some parts of the organization. Some areas such as global database requirements and regulatory requirements, however, must be considered for harmonization. The objective of a quality assurance (QA) audit is to ensure that QC systems are functioning correctly. Thus, statistics units should not depend on the audit work of QA groups to fulfill a QC role; errors detected by retrospective QA audits mean costly rework and delay. Statisticians should ensure they have adequate QC systems to build quality into the product.
Specification and Management of QC
Procedures and Tasks -The specification of analyses and reports must be agreed upon between "customer" and "supplier." Frequently, this will be achieved by reference to internal reporting standards which should be documented and accessible.
QC activities must focus on means of preventing nonconformance to the specification (by, eg, cross-checks, test data) as well as detecting errors through inspection. QC procedures in routine use must be specified in SOPs.
The objectives of and methods to be used for each QC task must be stated; "review the report" is not an adequate description. Check lists should be used.
The skills required for each QC task must be specified and training provided. Statistics management should ensure that it is resourced to meet QC needs, and not regard them as activities that can be squeezed in around "normal'' work. The discussions following the presentation of the key points in the paper were mostly based around SOP production, contents, and usage, including aspects of quality assurance and responsibility. SOPs are becoming an essential part of the pharmaceutical business, and production of company SOPs has been a key activity in recent years. On the regulatory side, the existence of SOPs is rare, and this was felt by the panelists to be an area which would benefit from having SOPs in place. Some units in the FDA have SOPs, but not all, although staff manual guides have been available to FDA reviewers for 15 years. It was anticipated that the FDA will produce documents detailing the review process, and that an overview SOP was required to increase consistency between the reviewing divisions. The point was made that if regulatory authorities are going to use external expert reviewers, SOPs were going to play an important part in assuring consistency of review.
SOPs are difficult documents to produce, requiring commitment and effort. In order to be effective, they need to be practical, but not too detailed. SOPs usually need to be developed and agreed upon internationally, which can involve a complete review and revision of the current processes. The ownership of these documents needs to lie with upper management to ensure the necessary commitment. When developing international procedures, it was recognized that there may be differences in the way in which these were adhered to. A certain amount of compromise in the local processes involved may be required, but the principles outlined in the SOPs need to be achieved and maintained.
It was generally agreed that SOPs should be about the principles of what should be done and when, as well as outlining the responsibilities. SOPs should not include the detail of how to carry out tasks -these more detailed technical processes could be covered by additional documents to be used as guides, particularly when the SOP is international with the processes beneath it differing between countries. The inclusion of check lists within an SOP, however, was seen as helpful, and necessary.
One of the key elements of an SOP is to clearly define the interfaces between different working groups and departments within and outside the organization. The SOP can be used as a contract between the respective parties, and should be developed and agreed upon by those groups to whom the SOP will apply.
The amount of detail to be included in an SOP was a subject of much debate, and brought in the question of an audit against documents. A document which outlines the required processes in general terms, without specific details on responsibilities, timings, and requirements, would be unlikely to produce problems if used as an audit tool by a regulatory authority. This SOP, however, would not be a useful document to the company, and would not provide consistency. At the other extreme, too much detail in an SOP results in that procedure being much more difficult to comply with, and may cause problems under audit. It was noted that the draft CPMP guidelines include reference to validated computer software. One opinion was that more detail needs to be included on this topic, as mistakes are made during programming, particularly if a program is produced to perform a new statistical procedure. In this situation, validation is important. It was also noted that apparently validated software may not produce the right answer, and that major analyses should be compared using different software.
A subject which received major attention was the sign-off on protocols, study reports, and submissions by statisticians. Some members of the panel saw this as a vital part of the statistician's responsibilities, particularly given that statisticians are usually the most objective people taking part in the process of drug development, and the only members trained in the scientific interpretation of data. There was, however, a view that there are insufficient experienced statisticians with a perspective of drug development and the production of an integrated summary of efficacy and an integrated summary of safety to be able to make this a requirement of regulatory authorities. This area was seen as a possible niche for contract organizations.
There was concern that should the signoff of clinical reports and higher level documents be made a requirement in a regulatory guideline, pressure may be applied by companies on statisticians to sign. What would the consequences be should they refuse to do so? It was felt that the philosophy of the companies needed to change, recognizing the value of statisticians, rather than having sign-off of documents imposed. On a similar line of discussion, it was noted that the introduction of the FDA guidelines had a major effect on the employment of statisticians in pharmaceu-tical companies, and on the responsibilities held by these statisticians. There was also comment that in Europe the lack of inspections by regulatory authorities has meant less emphasis being placed on the importance of statistics.
A regulatory member of the panel commented that the statistical review of expert reports would be valuable, as these can contain conclusions which are not in accordance with the findings of the clinical studies. Statistical review could prevent this, and lead to objective data driven conclusions.
SOPs can be used by biometrics groups to train staff on the processes involved in drug development and individual responsibilities. Regular training events were seen as important, and it was noted that dedicated resources are needed to enable this to happen.
Quality control and quality assurance were two areas where the use of SOPs were seen to be vital. Both elements should be built into the SOPs, and both the company and regulatory authorities can audit against the SOPs. SOPs themselves provide documentation of the quality standard expected, and the use of check lists and other forms as part of compliance with the SOPs can provide documentation of quality. There was a suggestion that this may speed up the review process.
A question asked by a member of the audience centered around the adequate training of statisticians to be able to carry the responsibility for a quality product, and compliance with SOPs. This resulted in a discussion which moved away somewhat from the subject of SOPs, and returned to the training of statisticians and the sign-off on clinical reports and packages.
It was suggested that the universities could do more to educate students in the skills needed for specific jobs, and be aware of the areas for which their courses are applicable. It was recognized, however, that it was not possible to do all the necessary training within the university, and that employers have a responsibility, too. A very relevant comment made was that education never stops, and that selfdevelopment should be encouraged. In addition, the university level may not be the appropriate place for this training, as many students do not have a defined career path at this stage. It was suggested that companies should explicitly give responsibility for statistical training to one statistician as that person's main job role. This was seen as the best way of guaranteeing ongoing training. The concept of mentoring was also seen as extremely useful in the work environment, and could provide greater on-the-job training. Placing the responsibility of training staff in the hands of the employer also gives individuals opportunities and scope for development within the company.
The discussion had to be closed due to time constraints, and had the potential to continue for some time. The quality control of statistical contributions was not discussed in as much detail as SOPs, and the discussion became sidetracked somewhat by the issue of training. The following points formed the closing summary:
Responsibilities need to be clearly defined, and should be addressed explicitly in SOPs, SOPs should be produced as the level of principle, and not contain the detail, SOPs are appropriate for regulatory agencies, as well as sponsors, Check lists were considered to be very useful in terms of clarifying the processes, and as a training aid, The fact that software is validated does not preclude quality control of the output, There is a need for guidance for the experts involved in the production of expert reports, and in the review of submissions, Job-specific training needs to be a company responsibility, and statisticians need to remember that education is an ongoing activity, and There was a move toward statisticians being responsible for signing off on major study reports and higher level documents, including the expert report.
In conclusion, the possibility for the pharmaceutical statistician to play a much greater role in drug development was highlighted by the discussion. Efficiency and effectiveness are going to be the key words in the future, and with the objective analytical training that the statistician receives, he/she is ideally placed to take the initiative and contribute to drug development in much broader terms than as just "data analysts."
